Exercise before chemotherapy for ovarian cancer patients
Official title: Effect of Exercise Preconditioning in Ovarian Cancer on Treatment-Related Cardiotoxicity
Run by University of Virginia · NCT05029154 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study tests if starting an exercise program before chemotherapy can help women with ovarian cancer feel better and reduce side effects during their treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 27 (estimated) |
| Sponsor | University of Virginia Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Charlottesville, Virginia) |
| Trial ID | NCT05029154 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 18 and older with a confirmed diagnosis of ovarian cancer who are about to start chemotherapy.
✕Probably not a fit
Patients with cancer recurrence or those who have had chemotherapy in the past five years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates whether initiating exercise prior to chemotherapy can reduce the negative side effects associated with treatment for ovarian cancer, such as cardiovascular issues and neuropathy. Participants will engage in high-intensity interval exercise, with the aim of preserving cardiovascular function and improving quality of life during and after chemotherapy. The study focuses on newly diagnosed women who are scheduled for surgery and chemotherapy, assessing the impact of sustained exercise throughout their treatment.
Why it matters
Potential benefit: If successful, this approach could enhance the quality of life and overall health outcomes for ovarian cancer patients undergoing chemotherapy.
How similar studies have gone: Previous studies have shown promise in using exercise to mitigate chemotherapy side effects, suggesting a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or over * Presumed diagnosis of ovarian cancer and a planned chemotherapy regimen of a taxane and carboplatin with or without VEGF inhibition * Physician clearance for exercise training Exclusion Criteria: * Any patient unable/unwilling to cooperate with all study protocols * Cancer recurrence * Previous treatment with chemotherapy in the last 5-years * Medical/orthopedic co-morbidities that preclude exercise training * Significant heart, liver, kidney, blood, or respiratory disease precluding exercise participation * Peripheral vascular disease * Acute infectious disease or history of chronic infections
Where it's running
-
University of Virginia University Hospital
Charlottesville, Virginia, United States Recruiting
Study contacts
- Principal investigator: Siddhartha S Angadi, PhD — University of Virginia
- Study coordinator: Siddhartha S Angadi, PhD
- Email: ssa2w@virginia.edu
- Phone: 434-243-7466
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.